ML290 is a biased allosteric agonist at the relaxin receptor RXFP1

Martina Kocan; Mohsin Sarwar; Sheng Y Ang; Jingbo Xiao; Juan J Marugan; Mohammed A Hossain; Chao Wang; Dana S Hutchinson; Chrishan S Samuel; Alexander I Agoulnik; Ross AD Bathgate; Roger J Summers

Journal article

ML290 is a biased allosteric agonist at the relaxin receptor RXFP1

Martina Kocan, Mohsin Sarwar, Sheng Y Ang, Jingbo Xiao, Juan J Marugan, Mohammed A Hossain, Chao Wang, Dana S Hutchinson, Chrishan S Samuel, Alexander I Agoulnik, Ross AD Bathgate, Roger J Summers

Scientific Reports | NATURE PUBLISHING GROUP | Published : 2017

DOI: 10.1038/s41598-017-02916-5

Download PDF

University of Melbourne Researchers

Akhter Hossain Author Florey Department of Neuroscience and Mental Health

Chrishan Samuel Author Biochemistry and Pharmacology

Ross Bathgate Author Florey Department of Neuroscience and Mental Health

Martina Kocan Author Florey Department of Neuroscience and Mental Health

Related Projects (3)

Determining modes of binding and activation of complex G-protein coupled receptor targets

The peptide hormones relaxin is currently in a Phase III trial for the treatment of heart failure. However the peptide is not a good drug as..

RESEARCH FELLOWSHIP

Relaxin family peptides are small proteins that have numerous essential biological roles in the vascular system, brain and gut. The hormone ..

Functional analysis of relaxin and INSL3 receptors

The peptide hormone relaxin is currently in clinical trials to treat acute heart failure. The related hormone INSL3 has important roles in f..

Grants

Awarded by National Health and Medical Research Council of Australia

Awarded by National Health and Medical Research Council Program

Awarded by Australian Research Council

Awarded by National Cancer Institute

Awarded by NATIONAL CANCER INSTITUTE

Awarded by NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES

Funding Acknowledgements

We thank Sharon Layfield and Tania Ferraro for technical assistance, Dr Melanie White (Australian Institute for Regenerative Medicine, Monash University) for the pENTR L1-R5 Ef1 alpha construct and Prof. Alon Chen (Weizmann Institute of Science, Israel) for the gift of pMDL, pRev and pVSVG plasmids. Research at the Florey was supported by National Health and Medical Research Council of Australia project grants 628427 and 1043750 (RADB) and by the Victorian Government Operational Infrastructure Support Program. CSS 1041766 and RADB 1042650 are NHMRC Senior Research Fellows and DSH 545952 is an NHMRC Career Development Fellow. Research at Drug Discovery Biology, Monash Institute of Pharmaceutical Science was supported by National Health and Medical Research Council Program Grant 1055134 (RJS) and by Australian Research Council Linkage Grant LP110100288 (RJS, RADB, CSS) and Industry Partner Corthera Inc. Research at Florida International University was supported by National Cancer Institute grant U01CA177711 (AIA). (San Mateo, CA) who also supplied H2 relaxin.